FOXO factors are tumour suppressor proteins commonly inactivated in human tumours by posttranslational modifications. Furthermore, genetic variation within the FOXO3a gene is consistently associated with human longevity. Therefore, the pharmacological activation of FOXO proteins is considered as an attractive therapeutic approach to treat cancer and age-related diseases. In order to identify agents capable of activating FOXOs, we tested a collection of small chemical compounds using image-based high content screening technology. Here, we report the discovery of LOM612 (compound 1a), a newly synthesized isothiazolonaphthoquinone as a potent FOXO relocator. Compound 1a induces nuclear translocation of a FOXO3a reporter protein as well as endogenous FOXO3a and FOXO1 in U2OS cells in a dose-dependent manner. This activity does not affect the subcellular localization of other cellular proteins including NFkB or inhibit CRM1-mediated nuclear export. Furthermore, compound 1a shows a potent antiproliferative effect in human cancer cell lines.
                                    FOXO 因子是肿瘤抑制蛋白,通常通过翻译后修饰在人类肿瘤中失活。此外,FOXO3a 
基因内的遗传变异始终与人类长寿相关。因此,FOXO蛋白的药理学激活被认为是治疗癌症和年龄相关疾病的一种有吸引力的治疗方法。为了识别能够激活 FOXO 的试剂,我们使用基于图像的高内涵筛选技术测试了一系列小化合物。在这里,我们报告了 LOM612(化合物 1a)的发现,这是一种新合成的
异噻唑啉
萘醌,可作为有效的 FOXO 重定位剂。化合物 1a 以剂量依赖性方式诱导 U2OS 细胞中 FOXO3a 报告蛋白以及内源性 FOXO3a 和 FOXO1 的核转位。此活性不会影响其他细胞蛋白(包括 NFkB)的亚细胞定位,也不会抑制 CRM1 介导的核输出。此外,化合物 1a 在人类癌
细胞系中显示出有效的抗增殖作用。